IL-23psoriasisrisankizumabtildrakizumabIL‐23 inhibitors have shown long‐term efficacy and safety for the treatment of moderate‐to‐severe plaque psoriasis in adults. Guselkumab has also been approved to treat psoriatic arthritis while tildrakizumab and risankizumab are currently under ...
银屑病患者使用IL-17和IL-23抑制剂后具有较高的药物生存期,其中古塞奇尤单抗和瑞莎珠单抗的药物生存期最高。 参考文献: Thomas SE, Barenbrug L, Hannink G, Seyger MMB, de Jong EMGJ, van den Reek JMPA. Drug Survival...
Among these, inhibitors of interleukin-23 (e.g., ustekinumab, guselkumab, tildrakizumab, and risankizumab) have emerged as safe and effective options for the treatment of moderate-to-severe plaque psoriasis; ustekinumab and guselkumab have additionally been approved to treat psoriatic arthritis. ...
Mechanism of action and dosing of IL-23 inhibitors use to treat plaque psoriasis as explained by advanced practice providers.
2.Tsiogka A, Gregoriou S, Stratigos A, et al. The impact of treatment with IL-17/IL-23 inhibitors on subclinical atherosclerosis in patients with plaque psoriasis and/or psoriatic arthritis: a systematic review. Biomedic...
Experts in psoriasis examine the implications of long-term data for IL-23 inhibitors, especially in patients who have not responded to initial treatment of plaque psoriasis.This is a modal window. This video is either unavailable or not supported in this browserError Code: MEDIA_ERR_SRC_NO...
IL-23 and IL-12/23 inhibitorsDisproportionality analysisPharmacovigilanceInterleukin-23 (IL-23) inhibitors and the IL-12/23 inhibitor ustekinumab constitute a pivotal class of therapeutic agents employed in the clinical management of Psoriasis, a chronic immune-mediated skin disorder. Notwithstanding their...
IL-12 和 IL-23 共同亚基 p40 及其受体 IL-12Rβ1 亚基, 且 IL-23 主要在真皮细胞表达,银屑病中 p40 的免疫反应性增加,支持 p40 亚基作为治疗靶点。已有多款靶向 p40 的单克隆抗体,如乌司奴单抗 (Ustekinumab) (详情:https://www.medchemexpress.cn/Ustekinumab.html)和布雷奴单抗 (Briakinumab)(详情:ht...
The objective of this study is to assess whether controlled DR of interleukin (IL)-17 and IL-23 inhibitors in psoriasis patients with low disease activity is non-inferior (NI) to usual care (UC). Methods This is an international, prospective, multicenter, pragmatic, randomized, non-inferiority...
[1]https://www.iqvia.com/blogs/2021/02/interleukin-inhibitors-to-continue-driving-psoriasis-market-growth [2]杨君义, 等. 中国医院药学杂志. 2018; 11: 1236-1239. [3]Girolomoni G, et al. J Eur Acad Dermatol Venereol. 2...